TREATMENT-RESISTANT DEPRESSION (TRD)

WHAT IS *Treatment-Resistant Depression?*

TRD occurs when people with major depressive disorder (MDD)* are failed by at least two different antidepressant treatments and still have not experienced meaningful relief, despite taking the treatments as recommended.[1]

*MDD, or clinical depression, causes ongoing sadness, hopelessness and loss of interest that lasts at least two weeks.[2]

PREVALENCE *and Key Facts*

~4M people in the U.S. with MDD are estimated to live with TRD.[1]

Women, veterans and members of the LGBTQ+ community are more likely to experience TRD.[3-5]

DISEASE *Impact*

TRD places a significant burden on those living with the condition, their loved ones and the communities around them.

COMPARED TO PEOPLE WHO HAVE MDD, THOSE WITH TRD EXPERIENCE:

70%	Greater work time loss[6]
17–30%	Increased risk of death from any cause[7-8]
51%	Increased risk of mortality due to suicide[8]
~3x	Longer depressive episodes on average[9]
⌃⌃	Rates of pain, anxiety and migraines[10]

23+ HOURS

Caregivers devote **~23 hours each week on average** to supporting a loved one with TRD[11]

UNMET *Need*

55+ APPROVED TREATMENTS for MDD

2 FDA-APPROVED MEDICINES for TRD[12]

Many people with TRD are **repeatedly treated with similar approaches that have already failed them**, while clinical guidelines for physicians offer limited guidance after multiple treatment failures.[13, 14]

Current treatment options used to treat TRD face significant challenges, including:

- ✕ INCONSISTENT EFFECTIVENESS
- ✕ LIMITED ACCESSIBILITY
- ✕ TOLERABILITY ISSUES

Early and effective intervention is critical to preventing TRD disease progression. Timely use of TRD-indicated treatments may improve responsiveness and long-term outcomes.[15-17]

If you are experiencing emotional distress, having thoughts of harming yourself, or feel that you may be in immediate danger, please contact a healthcare professional or seek help right away. In the United States, call or text 988 to reach the Suicide & Crisis Lifeline, available 24 hours a day, 7 days a week. If you are in immediate danger, call 911 or go to the nearest emergency room.

References:
[1]Wing V, et al. Poster 597 Contemporary Estimate of the National Prevalence of Treatment-Resistant Depression in the United States. J Mood Anxiety Disord. Presented at ADAA 2026
[2]Cleveland Clinic. "What Is Major Depressive Disorder?" https://my.clevelandclinic.org/health/diseases/24481-clinical-depression-major-depressive-disorder. Accessed August 13, 2026
[3]da Silva FER, et al. Journal of Neurochemistry. 2025;169(3):e70215
[4]Ellis S, et al. J Affect Disord. 2025;389:119655
[5]Cha F, et al. J Clin Psychiatry. 2022;83(4):21m14321
[6]Amos TB, et al. J Clin Psychiatry. 2018;79(2):17m11725
[7]Lundberg J, et al. JAMA Psychiatry. 2023;80(2):167-175
[8]Gustafsson TT, et al. J Affect Disord. 2025;368:136-142
[9]Wu B, et al. PLoS One. 2019;14(8):e0220763
[10]Kubitz N, et al. PLoS One. 2013;8(10):e76882
[11]Compass Pathways data on file
[12]NAMI. "What Medication Changes Can Be Made For Treatment-Resistant Depression?" https://www.nami.org/treatments-and-approaches/mental-health-medications/treatment-resistant-depression/. Accessed October 5, 2026.
[13]McIntyre RS, et al. World Psychiatry. 2023;22(3):394-412
[14]Adapted from Kasper S, et al. World J Biol Psychiatry. 2021;22(6):468-482
[15]Turkoz I, et al. Psychiatry Res. 2023;323:115165
[16]Rovers JIE, et al. Acta Psychiatr Scand. 2023;147(6):570-580
[17]Lisanby SH, et al. Neuropsychopharmacology. 2009;34(2):522-534

©2026 COMPASS PATHWAYS

REV2026OCT05